A post hoc analysis of the WARSS trial showed a reduction in the risk of stroke or death among those assigned warfarin rather than aspirin among the 5% of patients with the highest levels of NT‐proBNP (Longstreth et al., 2013). This evidence concerns the gene NPPB and stroke disorder.